Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s): AQSZF

Healthcare

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.

TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc

Bullboard Posts

Comment by Njdevilsfanon Aug 31, 2017 11:39am

121 Views

Post# 26642318

RE:RE:RE:Q2 Financials

so when the company is predicting $30+ million in revenue around 2018 or so and this quarters revenue is under $200,000, that is strong revenues? 58% increase really isn't that impressive when it's based on such a small number. also, revenues fluctuate for this company so who knows if they will keep it up.

Bullboard Posts

Visionstate set to leverage success in the U.S. market